Insight Molecular Diagnostics (IMDX) Change in Account Payables (2015 - 2020)

Insight Molecular Diagnostics has disclosed Change in Account Payables across 6 years of filings, most recently posting -$6000.0 for Q1 2020.

• Change in Account Payables for Q1 2020 came in at -$6000.0, up 99.71% year-over-year; the trailing twelve-month figure through Dec 2020 was -$6000.0 (up 99.71% YoY), and the FY2020 annual result was -$6000.0, up 99.71% from the prior year.
• Change in Account Payables came in at -$6000.0 for Q1 2020 at Insight Molecular Diagnostics, down from $6000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $624000.0 in Q1 2016 to a low of -$2.1 million in Q1 2019.
• The 5-year median for Change in Account Payables is -$3000.0 (2017), against an average of -$49647.1.
• Across the five-year window, Change in Account Payables surged 1248.39% in 2016 and slumped 30114.29% in 2019, its largest moves.
• Insight Molecular Diagnostics' Change in Account Payables stood at $597000.0 in 2016, then tumbled by 100.5% to -$3000.0 in 2017, then slumped by 233.33% to -$10000.0 in 2018, then surged by 160.0% to $6000.0 in 2019, then slumped by 200.0% to -$6000.0 in 2020.
• The last three Change in Account Payables figures came in at -$6000.0 (Q1 2020), $6000.0 (Q4 2019), and -$4000.0 (Q3 2019), per Business Quant data.